UFUwe M. Fischer

Uwe M. Fischer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Uwe M. Fischer has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Uwe Mehlhorn

    Department of Cardiothoracic Surgery , University of Cologne, Joseph-Stelzmann-Str. 9, 50924 Cologne , Germany

    2 shared publications
  • A. Kroener

    Department of Thoracic and Cardiovascular Surgery, University of Cologne, Germany

    1 shared publication
  • Albert Antonyan

    Institute I for Anatomy , University of Cologne, Joseph-Stelzmann-Str. 9, 50924 Cologne , Germany

    1 shared publication
  • C. Menzel

    Department of Thoracic and Cardiovascular Surgery, University of Cologne, Germany

    1 shared publication
  • H. J. Geissler

    Department of Thoracic and Cardiovascular Surgery, University of Cologne, Germany

    1 shared publication
  • Khosro Hekmat

    Department of General, Visceral and Thoracic Surgery, University Hospital of Cologne, 50937 Cologne, Germany

    1 shared publication

Latest Publications

  • Open Access

    Impact of antioxidative treatment on nuclear factor kappa-B regulation during myocardial ischemia-reperfusion

    by Uwe M. Fischer, Albert Antonyan, Wilhelm Bloch, Uwe Mehlhorn

    Nuclear factor kappa-B (NFκB), a transcription factor, plays a role in numerous pathological states such as myocardial ischemia–reperfusion (I/R), apoptosis, and ischemic preconditioning. As both myocardial ischemia and reperfusion (by reactive oxygen intermediates) can activate NFκB, we investigated the impact of the antioxidant N-acetylcysteine (NAC) on NFκB-regulation in patients subjected to cardioplegic arrest (CA) on cardiopulmonary bypass (CPB). Seventeen coronary artery surgery patients (66±9[S.D.] years) subjected to cardiopulmonary bypass (CPB) and cardioplegic arrest were randomized in a double-blind fashion to receive either NAC (100 mg/kg into CPB prime followed by infusion at 20 mg/kg/h; n=9) or placebo (n=8). Transmural LV biopsies were collected prior to CPB (baseline) and at CPB-end and immuno-cytochemically stained against active NFκB and phosphorylated IκBα (activates NFκB). At the end of CPB both NFκB and IκBα were unchanged in endothelial cells of controls compared to baseline (45.6±7.6 vs. 49.9±7.1 and 36.8±6.1 vs. 47.5±8.6 counts per viewfield (cpv), P>0.05, respectively). In NAC, NFκB and IκBα in endothelial cells were significantly decreased at CPB-end (19.8±1.7 vs. 39.1±4.1 cpv, PP=0.006). In cardiomyocytes, however, there were no changes observed in either group. Antioxidative treatment with NAC decreases NFκB-activity follwing I/R in endothelial cells. We conclude that NFκB-activity post I/R is mediated by free radicals rather than ischemia alone.


  • Renal protection by radical scavenging in cardiac surgery patients

    by Uwe M. Fischer, Paschalis Tossios, Uwe Mehlhorn

    Objective: Renal function impairment is a common complication in cardiac surgery patients. Because cardiopulmonary bypass and cardioplegic arrest are associated with formation of free radicals, which have been shown to impair various organs including the kidneys, radical scavenging may protect renal function. Therefore, the purpose of our study was to evaluate the impact of the radical scavenger N-acetylcysteine (NAC) versus placebo on peri-operative renal function in cardiac surgery patients.Research design and methods: We reanalyzed the data of our previous study in which 40 coronary artery surgery patients (66 ± 9 [SD] years, 9 women and 31 men) with normal pre-operative renal function had been randomized in a double-blind fashion to receive either NAC (100 mg/kg into the cardiopulmonary bypass prime followed by infusion at 20 mg/kg/h; n = 20) or placebo (n = 20). We determined serum creatinine levels as an indicator for renal function pre- and at 1 day post-surgery as well as peri-operative ur...


  • The effect of preoperative antiplatelet therapy in coronary artery surgery: blood transfusion requirements for patients on cardiopulmonary bypass

    by K. Hekmat, C. Menzel, A. Kroener, R. H. G. Schwinger, S. Kampe, U. M. Fischer, H. J. Geissler, U. Mehlhorn

    Introduction: Bleeding after heart operations remains a common complication and contributes to morbidity and death. Recent studies have suggested that antiplatelet therapy (APT) may not increase homologous blood requirements in coronary bypass surgery. The purpose of this study was to examine the influence of APT therapy on haemorrhage and transfusion requirements in patients undergoing coronary artery bypass (CABG) on cardiopulmonary bypass (CPB). Materials and methods: Records from 290 consecutive patients who underwent CABG with CPB were retrospectively reviewed, including 145 patients who received APT within 5 days prior to surgery and 145 control patients (CON). Blood loss was measured up to 24 h. Demographic and clinical patient data were collected until hospital discharge. Results: Both groups were well matched with respect to demographic and intra-operative data. There was significantly ( p < 0.0005) more mediastinal tube drainage at 24 h in the APT group (1123 mL ± 537 mL) compared to CON patients (874 mL ± 351 mL). In addition, the APT group received significantly more units of blood (APT: 2.6 ± 2.5 vs CON: 1.6 ± 1.8; p < 0.0005), platelet units (APT: 1.2 ± 1.8 vs CON: 0.2 ± 0.8; p < 0.0005), and fresh frozen plasma units (APT: 2.0 ± 2.2 vs CON: 1.3 ± 2.0; p = 0.01). Conclusion: This study suggests consideration should be given to delaying elective CABG for patients who have received APT treatment until APT is discontinued for at least 5 days.